Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Safety Study in Asian NSCLC Patients
NCT03195491Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03195491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195491.